Last reviewed · How we verify
Extended-Release Buprenorphine Injection — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Extended-Release Buprenorphine Injection (Extended-Release Buprenorphine Injection) — NYU Langone Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Extended-Release Buprenorphine Injection TARGET | Extended-Release Buprenorphine Injection | NYU Langone Health | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Extended-Release Buprenorphine Injection CI watch — RSS
- Extended-Release Buprenorphine Injection CI watch — Atom
- Extended-Release Buprenorphine Injection CI watch — JSON
- Extended-Release Buprenorphine Injection alone — RSS
Cite this brief
Drug Landscape (2026). Extended-Release Buprenorphine Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-release-buprenorphine-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing